An Indian contract research organisation (CRO) should not assume a clinical-trial service is GST-free just because its sponsor is overseas. First identify the contracted services and parties, determine the place of supply—including whether the pharmaceutical R&D notification applies—and test every statutory export condition. If the supply qualifies as an export, it is zero-rated; otherwise, the CRO must establish the applicable classification and rate before deciding how GST appears in its quote.
What determines whether a CRO should charge GST?
The result depends on the actual supply, not just the label “clinical research” or the location of the sponsor. For a cross-border service, the place of supply is central to whether the service can meet the export test. A foreign sponsor and payment from abroad are relevant facts, but neither alone makes a service a zero-rated export.
As an Amazon Associate I earn from qualifying purchases.
CDSCO describes a CRO as a body to which a sponsor may delegate or transfer in writing some or all tasks, duties, or obligations relating to a clinical trial or bioavailability/bioequivalence study. That breadth matters for pricing: a contract may cover multiple activities, deliverables, and responsibilities, rather than one undifferentiated service. CDSCO also states that a valid clinical-trial agreement should be in place before trial-related activity begins.
How to assess GST before preparing the quote
- Set out the actual scope. Map the contracted responsibilities, deliverables, milestones, trial activities, and any bundled or separately identifiable services. Keep the statement of work aligned with what the CRO will actually do.
- Identify the supplier and recipient. Record the Indian legal entity that will invoice and the sponsor entity receiving the service. Check whether the recipient is a separate legal person or merely another establishment of the same person; the statutory export test excludes supplies between establishments of a distinct person.
- Determine the place of supply. Under section 13(2) of the IGST Act, the general rule for cross-border services is the recipient’s location, subject to exceptions. Section 13(3) addresses specified services connected with goods made physically available to the supplier and services to an individual who must be physically present with the supplier. Section 13 also provides for notified rules based on effective use and enjoyment. The fact that trial work, sites, or participants are in India does not, by itself, settle the place-of-supply question.
- Check the pharmaceutical R&D notification against the contracted services. The GST Council’s 37th Meeting material identifies clinical trials among pharmaceutical-sector R&D services for which place of supply would be notified by effective use and enjoyment. CBIC’s notification index identifies Notification 4/2019-Integrated Tax, dated 30 September 2019, as a section 13(13) notification concerning pharmaceutical-sector R&D services. Review the operative notification, its conditions, and any amendments against the CRO’s specific service components before reaching a conclusion.
- Test every export condition. Section 2(6) of the IGST Act requires that the supplier be in India, the recipient be outside India, the place of supply be outside India, consideration be received in foreign exchange or in Indian rupees where permitted by the Reserve Bank of India, and the supplier and recipient not be merely establishments of a distinct person. The conditions are cumulative.
- Set the quote and tax process. If the supply qualifies, document the basis for treating it as zero-rated and confirm current bond/letter of undertaking (LUT) and refund requirements. If it does not, confirm the service classification and applicable rate using the current rules and rate notifications before stating the tax treatment in the quote.
What zero-rated treatment means for pricing
Zero-rated is not the same as an exempt domestic supply. Under section 16 of the IGST Act, exports of goods or services and specified supplies to special economic zones are zero-rated supplies. Subject to the Act and rules, a registered supplier may make a zero-rated supply without payment of IGST under bond or LUT and claim a refund of eligible unutilised input tax credit. Credit remains subject to statutory restrictions, including section 17(5) of the CGST Act.
#1 Best Overall
Accordingly, zero-rating does not mean that GST-related costs or cash-flow effects disappear. A CRO should model eligible input credits and the timing of any refund rather than assume an immediate refund or add an unsupported GST premium to its fee.
How the two quote treatments differ
| Quote treatment | When it may apply | What the CRO should establish | Pricing and administration implications |
|---|---|---|---|
| Zero-rated export | Only when all section 2(6) export conditions are met, including a place of supply outside India. | The recipient and supplier entities, place-of-supply basis, qualifying payment, and evidence supporting the export treatment. | Confirm the applicable bond/LUT and refund process; account for eligible input-credit and refund timing in cash flow. |
| Taxable supply | When the service does not qualify as a zero-rated export, based on the applicable facts and rules. | The correct service classification, treatment of any bundled components, and current rate. | State whether the fee is exclusive or inclusive of applicable GST and explain how a reasoned tax determination or change will be handled. |
The table describes the decision framework, not a conclusion for any particular CRO engagement. There is no single GST rate established for every clinical-trial service bundle. CBIC’s rate table lists 18% for “other services” under heading 9989, but that entry alone does not establish that every CRO service falls under that heading.
Why the 2019 Maharashtra advance ruling is not a universal answer
On 4 May 2019, the Maharashtra Authority for Advance Ruling considered Cliantha Research Limited’s proposed clinical-research services for entities outside India. The ruling illustrates the fact-sensitive legal question, but it is a specific advance ruling and predates Notification 4/2019-Integrated Tax of 30 September 2019. It should not be treated as a universal determination that all Indian CRO services are taxable, or that all qualify as exports. Its reasoning and scope need to be considered alongside the later notification and the current contract facts.
What to put in the commercial terms
- Separate the professional or service fee from expressly identified pass-through or reimbursable items. Do not assume that a reimbursement falls outside the taxable value; determine the treatment of each item.
- Specify whether the quoted fee is exclusive or inclusive of applicable GST. Set out how the parties will address a tax determination or change, based on a documented review.
- Identify the customer entity, its country and address, the contracting and invoicing entities, and the payment currency and route. Retain evidence that supports the recipient identity and receipt of consideration.
- Align the statement of work with the actual activities, deliverables, sites, and parties. Where a bundle contains separately identifiable components, describe them accurately rather than relying on a generic “clinical research” label.
- Model eligible input tax credit and refund timing as cash-flow items. Do not assume immediate recovery or build in a market-wide GST premium unsupported by the specific analysis.
These are practical contract and pricing controls, not prescribed universal clauses. The cited statutory and administrative materials establish the framework; they do not determine the GST treatment of a particular CRO’s contract. Obtain contract-specific Indian GST advice before fixing the tax clause or claiming zero-rating.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
